Six complete genome sequences of Cydia pomonella granulovirus (CpGV) isolates from Mexico (CpGV-M and CpGV-M1), England (CpGV-E2), Iran (CpGV-I07 and CpGV-I12), and Canada (CpGV-S) were aligned and analyzed for genetic diversity and evolutionary processes. The selected CpGV isolates represented recently identified phylogenetic lineages of CpGV, namely, the genome groups A to E. The genomes ranged from 120,816 bp to 124,269 bp. Several common differences between CpGV-M, -E2, -I07, -I12 and -S to CpGV-M1, the first sequenced and published CpGV isolate, were highlighted. Phylogenetic analysis based on the aligned genome sequences grouped CpGV-M and CpGV-I12 as the most derived lineages, followed by CpGV-E2, CpGV-S and CpGV-I07, which represent the most basal lineages. All of the genomes shared a high degree of co-linearity, with a common setup of 137 (CpGV-I07) to 142 (CpGV-M and -I12) open reading frames with no translocations. An overall trend of increasing genome size and a decrease in GC content was observed, from the most basal lineage (CpGV-I07) to the most derived (CpGV-I12). A total number of 788 positions of single nucleotide polymorphisms (SNPs) were determined and used to create a genome-wide SNP map of CpGV. Of the total amount of SNPs, 534 positions were specific for exactly one of either isolate CpGV-M, -E2, -I07, -I12 or -S, which allowed the SNP-based detection and identification of all known CpGV isolates.
With the European Union (EU) Health Technology Assessment (HTA) regulation, Joint Clinical Assessments (JCA) are now required for oncological and advanced therapy medicinal products. The JCA assessment scope is determined through the PICO framework (Population, Intervention, Comparator, Outcome). Given the tight JCA timelines, Health Technology Developers (HTD) must anticipate PICO elements early to prepare dossiers effectively. This study investigates whether PICO can be predicted across EU member states using publicly available information. A systematic literature review was conducted to identify relevant peer-reviewed articles. Additionally, an extensive search of publicly available HTA documents, including reports, methodological guidelines, submission templates, and market access information was performed across 29 European countries. Relevant information for PICO anticipation was extracted. For many member states, a wealth of relevant information is publicly accessible: 66% have HTA reports publicly available, 79% have HTA methodological guidelines, 69% have dossier templates, and 100% have market access status lists. Between countries, the requirements for population and outcomes are largely aligned, making comparator the central element in PICO anticipation. PICO can be anticipated reliably based on public information. HTDs must be prepared to adjust their strategies as national procedures adapt, ensuring alignment with both current and emerging EU and national requirements.
Purpose This study provides a comprehensive analysis of the real-world epidemiology of histologically assessed IDH-mutated or IDH-wildtype grade II and III gliomas in Germany between 2009 and 2021, supplemented with a literature-based approach of setting the data in the context of the WHO 2021 classification. Methods Data from the Centre for Cancer Registry Data (ZfKD) at the Robert Koch-Institute (RKI) was utilized, encompassing all incident cases of histologically (according to the WHO classification of the respective time) newly diagnosed grade II and III gliomas diagnosed between 2009 and 2021, representing a subgroup of the total number of 14,053 glioma cases (including high grade glioma). Data were supplemented with an exploratory literature review on IDH-mutation rates and epidemiology data from the German low-grade glioma (LoG-Glio) disease registry. Results The tumor class distribution of newly diagnosed gliomas showed the majority being classified as grade IV glioma and only 9.0% and 9.2% as grade II or III, respectively. The incidence remained stable over the observation period. Literature data indicate mutation rates of IDH of approximately 86% in grade II and 60% in grade III gliomas diagnosed using pre-WHO-2021 criteria. Applying these proportions to 2009–2021 mean incidence cases numbers in an estimate of 459 grade 2 and 328 grade 3 IDH-mutated gliomas (combining astrocytoma and oligodendroglioma) and an incidence rate of 0.6 and 0.5 per 100.000 population for newly diagnosed IDH-mutated gliomas in Germany. Conclusion This study gives an overview of the incidence of WHO grade 2 and grade 3 gliomas among the German population. Furthermore, this study highlights the need of molecular information being integrated into epidemiologic monitoring of gliomas to obtain more precise insights into survival and prognostic factors.
The Regulation (EU) 2021/2282 on health technology assessment (HTAR) harmonises clinical evidence assessment across Europe. However, national appraisal, pricing, and reimbursement processes remain divergent and could affect the efficiency of decision-making and patient access. Here we mapped the sequencing of national assessment, pricing, and reimbursement steps across 30 European countries. National pathways from marketing authorisation to reimbursed access were systematically identified and coded as categorical process sequences. Inpatient and outpatient pathways were analysed separately. Pathway dissimilarities were calculated using Optimal Matching and grouped by hierarchical clustering. We further explored whether clusters differed with regard to country-level indicators, including medicine availability, average time to access, gross domestic product, and healthcare expenditure. We found substantial procedural heterogeneity across countries in both inpatient and outpatient settings. Nevertheless, recurring pathway structures were identified. Across settings, the dominant distinction was between assessment-led pathways, in which evidence assessment precedes pricing and reimbursement steps, and pricing-led pathways, in which price formation occurs prior to assessment and reimbursement-related steps. Cluster membership was not associated with any country-level indicators. Our findings provide policymakers, agencies, and industry with a baseline for understanding national procedural heterogeneity and for evaluating how market access pathways evolve as the JCA is implemented.